Do analysts prefer NNNN or CV?

CapsoVision has a consensus price target of $8.50, indicating a potential upside of 45.30%. Given CapsoVision's stronger consensus rating and higher probable upside, analysts plainly believe CapsoVision is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CapsoVision 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger valuation & earnings, NNNN or CV?

Anbio Biotechnology has higher earnings, but lower revenue than CapsoVision. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 130.25 $6.40M N/A N/A CapsoVision $13.55M 21.61 -$25.32M -$0.47 N/A

Which has stronger valuation and earnings, CV or BVS?

Bioventus has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CapsoVision $13.55M 21.61 -$25.32M -$0.47 N/A Bioventus $568.09M 2.08 $22.73M $0.77 18.29

Is CV or BVS more profitable?

Bioventus has a net margin of 9.36% compared to CapsoVision's net margin of -214.74%. Bioventus' return on equity of 28.08% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -214.74% -177.85% -135.07% Bioventus 9.36% 28.08% 9.82%

Which has preferable earnings & valuation, CV or IRMD?

iRadimed has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CapsoVision $13.55M 21.61 -$25.32M -$0.47 N/A iRadimed $83.81M 13.41 $22.48M $1.79 49.09

Is CV or IRMD more profitable?

iRadimed has a net margin of 26.70% compared to CapsoVision's net margin of -214.74%. iRadimed's return on equity of 23.45% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -214.74% -177.85% -135.07% iRadimed 26.70% 23.45% 20.36%

CapsoVision (CV) Competitors

$5.85 +0.02 (+0.34%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$5.86 +0.02 (+0.26%)

As of 08/25/2026 05:29 PM Eastern

Compare

CV vs. DRTS, NNNN, PRCT, BVS, and IRMD

Should you buy CapsoVision stock or one of its competitors? CapsoVision's main competitors and comparable companies include Alpha Tau Medical (DRTS), Anbio Biotechnology (NNNN), PROCEPT BioRobotics (PRCT), Bioventus (BVS), and iRadimed (IRMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does CapsoVision compare to Alpha Tau Medical?

CapsoVision (NASDAQ:CV) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, Alpha Tau Medical had 4 more articles in the media than CapsoVision. MarketBeat recorded 5 mentions for Alpha Tau Medical and 1 mentions for CapsoVision. CapsoVision's average media sentiment score of 0.00 equaled Alpha Tau Medical'saverage media sentiment score.

Company	Overall Sentiment
CapsoVision	Neutral
Alpha Tau Medical	Neutral

Alpha Tau Medical has a net margin of 0.00% compared to CapsoVision's net margin of -214.74%. Alpha Tau Medical's return on equity of -138.12% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-214.74%	-177.85%	-135.07%
Alpha Tau Medical	N/A	-138.12%	-81.68%

CapsoVision has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	21.61	-$25.32M	-$0.47	N/A
Alpha Tau Medical	N/A	N/A	-$42.63M	-$1.04	N/A

2.7% of Alpha Tau Medical shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CapsoVision currently has a consensus target price of $8.50, indicating a potential upside of 45.30%. Alpha Tau Medical has a consensus target price of $12.80, indicating a potential downside of 12.93%. Given CapsoVision's higher probable upside, research analysts clearly believe CapsoVision is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Alpha Tau Medical beats CapsoVision on 7 of the 13 factors compared between the two stocks.

How does CapsoVision compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

CapsoVision has a consensus price target of $8.50, indicating a potential upside of 45.30%. Given CapsoVision's stronger consensus rating and higher probable upside, analysts plainly believe CapsoVision is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Anbio Biotechnology has higher earnings, but lower revenue than CapsoVision.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	130.25	$6.40M	N/A	N/A
CapsoVision	$13.55M	21.61	-$25.32M	-$0.47	N/A

In the previous week, Anbio Biotechnology had 1 more articles in the media than CapsoVision. MarketBeat recorded 2 mentions for Anbio Biotechnology and 1 mentions for CapsoVision. Anbio Biotechnology's average media sentiment score of 0.06 beat CapsoVision's score of 0.00 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Neutral
CapsoVision	Neutral

Anbio Biotechnology has a net margin of 0.00% compared to CapsoVision's net margin of -214.74%. Anbio Biotechnology's return on equity of 0.00% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
CapsoVision	-214.74%	-177.85%	-135.07%

Summary

Anbio Biotechnology beats CapsoVision on 7 of the 12 factors compared between the two stocks.

How does CapsoVision compare to PROCEPT BioRobotics?

CapsoVision (NASDAQ:CV) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 2.3% of CapsoVision shares are held by company insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CapsoVision currently has a consensus price target of $8.50, suggesting a potential upside of 45.30%. PROCEPT BioRobotics has a consensus price target of $28.00, suggesting a potential upside of 29.63%. Given CapsoVision's stronger consensus rating and higher probable upside, research analysts plainly believe CapsoVision is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
PROCEPT BioRobotics	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.19

In the previous week, PROCEPT BioRobotics had 42 more articles in the media than CapsoVision. MarketBeat recorded 43 mentions for PROCEPT BioRobotics and 1 mentions for CapsoVision. PROCEPT BioRobotics' average media sentiment score of 0.20 beat CapsoVision's score of 0.00 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.

Company	Overall Sentiment
CapsoVision	Neutral
PROCEPT BioRobotics	Neutral

CapsoVision has higher earnings, but lower revenue than PROCEPT BioRobotics. CapsoVision is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	21.61	-$25.32M	-$0.47	N/A
PROCEPT BioRobotics	$308.05M	4.02	-$95.57M	-$1.94	N/A

PROCEPT BioRobotics has a net margin of -32.53% compared to CapsoVision's net margin of -214.74%. PROCEPT BioRobotics' return on equity of -30.62% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-214.74%	-177.85%	-135.07%
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%

Summary

PROCEPT BioRobotics beats CapsoVision on 10 of the 15 factors compared between the two stocks.

How does CapsoVision compare to Bioventus?

CapsoVision (NASDAQ:CV) and Bioventus (NASDAQ:BVS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Bioventus has a net margin of 9.36% compared to CapsoVision's net margin of -214.74%. Bioventus' return on equity of 28.08% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-214.74%	-177.85%	-135.07%
Bioventus	9.36%	28.08%	9.82%

62.9% of Bioventus shares are held by institutional investors. 2.3% of CapsoVision shares are held by insiders. Comparatively, 33.5% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Bioventus had 1 more articles in the media than CapsoVision. MarketBeat recorded 2 mentions for Bioventus and 1 mentions for CapsoVision. CapsoVision's average media sentiment score of 0.00 beat Bioventus' score of -0.20 indicating that CapsoVision is being referred to more favorably in the media.

Company	Overall Sentiment
CapsoVision	Neutral
Bioventus	Neutral

CapsoVision presently has a consensus target price of $8.50, indicating a potential upside of 45.30%. Bioventus has a consensus target price of $16.80, indicating a potential upside of 19.32%. Given CapsoVision's higher probable upside, analysts clearly believe CapsoVision is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Bioventus has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	21.61	-$25.32M	-$0.47	N/A
Bioventus	$568.09M	2.08	$22.73M	$0.77	18.29

Summary

Bioventus beats CapsoVision on 12 of the 16 factors compared between the two stocks.

How does CapsoVision compare to iRadimed?

CapsoVision (NASDAQ:CV) and iRadimed (NASDAQ:IRMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

92.3% of iRadimed shares are held by institutional investors. 2.3% of CapsoVision shares are held by company insiders. Comparatively, 34.6% of iRadimed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CapsoVision currently has a consensus price target of $8.50, indicating a potential upside of 45.30%. iRadimed has a consensus price target of $120.00, indicating a potential upside of 36.57%. Given CapsoVision's higher probable upside, equities research analysts clearly believe CapsoVision is more favorable than iRadimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
iRadimed	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, iRadimed had 3 more articles in the media than CapsoVision. MarketBeat recorded 4 mentions for iRadimed and 1 mentions for CapsoVision. iRadimed's average media sentiment score of 1.41 beat CapsoVision's score of 0.00 indicating that iRadimed is being referred to more favorably in the news media.

Company	Overall Sentiment
CapsoVision	Neutral
iRadimed	Positive

iRadimed has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	21.61	-$25.32M	-$0.47	N/A
iRadimed	$83.81M	13.41	$22.48M	$1.79	49.09

iRadimed has a net margin of 26.70% compared to CapsoVision's net margin of -214.74%. iRadimed's return on equity of 23.45% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-214.74%	-177.85%	-135.07%
iRadimed	26.70%	23.45%	20.36%

Summary

iRadimed beats CapsoVision on 13 of the 15 factors compared between the two stocks.

Get CapsoVision News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CV vs. The Competition

Export

Metric	CapsoVision	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$291.77M	$5.95B	$7.35B	$12.72B
Dividend Yield	N/A	1.74%	2.53%	11.02%
P/E Ratio	-12.45	26.06	270.96	24.14
Price / Sales	21.61	70.35	642.82	101.63
Price / Cash	N/A	33.27	78.57	53.12
Price / Book	22.50	6.27	13.14	6.25
Net Income	-$25.32M	$149.30M	$3.46B	$347.86M
7 Day Performance	-4.41%	0.30%	1.51%	0.98%
1 Month Performance	-9.86%	9.23%	8.80%	5.24%
1 Year Performance	48.85%	6.92%	26.08%	17.04%

CapsoVision Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CV CapsoVision	2.3371 of 5 stars	$5.85 +0.3%	$8.50 +45.3%	+46.6%	$291.77M	$13.55M	N/A	90
DRTS Alpha Tau Medical	1.3345 of 5 stars	$14.15 -0.7%	$12.80 -9.5%	+357.9%	$1.29B	N/A	N/A	80
NNNN Anbio Biotechnology	1.0877 of 5 stars	$8.48 -3.0%	N/A	N/A	$1.26B	$8.65M	N/A	27	Short Interest Decrease High Trading Volume
PRCT PROCEPT BioRobotics	3.6953 of 5 stars	$21.09 -2.6%	$28.00 +32.8%	-45.1%	$1.24B	$308.05M	N/A	430	Trending News
BVS Bioventus	4.3878 of 5 stars	$13.88 -2.7%	$16.80 +21.0%	+89.2%	$1.20B	$568.09M	18.76	1,200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CV) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CapsoVision (CV) Competitors

CV vs. DRTS, NNNN, PRCT, BVS, and IRMD

How does CapsoVision compare to Alpha Tau Medical?

Summary

How does CapsoVision compare to Anbio Biotechnology?

Summary

How does CapsoVision compare to PROCEPT BioRobotics?

Summary

How does CapsoVision compare to Bioventus?

Summary

How does CapsoVision compare to iRadimed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CV vs. The Competition

CapsoVision Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CapsoVision (CV) Competitors

CV vs. DRTS, NNNN, PRCT, BVS, and IRMD

How does CapsoVision compare to Alpha Tau Medical?

Does the media refer more to CV or DRTS?

Is CV or DRTS more profitable?

Which has stronger earnings and valuation, CV or DRTS?

Do insiders and institutionals believe in CV or DRTS?

Do analysts recommend CV or DRTS?

Summary

How does CapsoVision compare to Anbio Biotechnology?

Do analysts prefer NNNN or CV?

Which has stronger valuation & earnings, NNNN or CV?

Does the media prefer NNNN or CV?

Is NNNN or CV more profitable?

Summary

How does CapsoVision compare to PROCEPT BioRobotics?

Do institutionals & insiders hold more shares of CV or PRCT?

Do analysts prefer CV or PRCT?

Does the media prefer CV or PRCT?

Which has higher earnings & valuation, CV or PRCT?

Is CV or PRCT more profitable?

Summary

How does CapsoVision compare to Bioventus?

Is CV or BVS more profitable?

Do institutionals & insiders have more ownership in CV or BVS?

Does the media prefer CV or BVS?

Do analysts recommend CV or BVS?

Which has stronger valuation and earnings, CV or BVS?

Summary

How does CapsoVision compare to iRadimed?

Do insiders & institutionals have more ownership in CV or IRMD?

Do analysts rate CV or IRMD?

Does the media favor CV or IRMD?

Which has preferable earnings & valuation, CV or IRMD?

Is CV or IRMD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CV vs. The Competition

CapsoVision Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools